Friday, October 30, 2026

Cellectis Eyes 2028 FDA Filing for Lasme-cel as Cash Runway Extends to Mid-2027

Cellectis plans to submit a Biologics License Application for lasme-cel to the FDA in 2028, targeting a leukemia treatment market the company projects could reach $700M in peak sales by 2035. The Paris-based biotech reported $225M in cash reserves as of September 30, 2025, funding operations into the second half of 2027. The regulatory milestone comes as Cellectis posted $62.6M in nine-month revenues, more than double the prior year period.

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Cellectis Eyes 2028 FDA Filing for Lasme-cel as Cash Runway Extends to Mid-2027
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Cellectis S.A. (NASDAQ: CLLS) anticipates filing a Biologics License Application for lasme-cel with the FDA in 2028, advancing its gene-edited CAR-T therapy toward commercialization. The company projects peak gross sales of $700M annually by 2035 across the U.S., U.K., and four major European markets, treating approximately 1,100 B-cell acute lymphoblastic leukemia patients yearly.

The clinical-stage biotech held $225M in cash and equivalents at the end of Q3 2025, down from $264M at year-end 2024. Management stated this runway extends into the second half of 2027. The cash position includes $168.2M in fixed-term deposits, with $137.6M maturing in October 2026.

Cellectis reported $62.6M in revenues for the nine months ended September 30, up from $28.8M in the same 2024 period. The increase stems primarily from collaboration activities with AstraZeneca. Third-quarter revenues alone totaled $35.2M, compared to $16.2M a year earlier.

The company narrowed its net loss to $41.3M for the nine-month period, versus $42.7M in 2024. Diluted loss per share improved to $0.41 from $0.49. Third-quarter results showed net income of $0.6M, reversing a $23.1M loss from Q3 2024.

Operating expenses held relatively flat. R&D spending declined slightly to $69.1M from $69.7M, while selling, general and administrative costs rose to $15M from $14.2M. The company attributed increased personnel costs to stock-based compensation.

Cellectis projects lasme-cel could generate up to $1.3B in peak sales if approved for expanded indications, including second-line treatment and first-line consolidation in minimal residual disease-positive patients. The allogeneic approach positions the therapy for higher margins compared to autologous CAR-T products.

The BLA filing timeline positions Cellectis for potential commercialization in 2029 or 2030, depending on FDA review duration. Manufacturing capacity exists at company facilities in Paris and Raleigh, North Carolina.

Average shares outstanding increased to 100.3M from 87.4M, reflecting equity financing activities. The company maintains partnerships with AstraZeneca and other pharmaceutical firms for its gene-editing platform.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]Press releaseGlobeNewswire· November 7, 2025
    Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com